Dementia with Lewy Bodies (DLB) is a progressive neurodegenerative disorder characterized by cognitive decline, visual hallucinations, parkinsonism, and fluctuating cognition. It is pathologically defined by the presence of Lewy bodies containing aggregated alpha-synuclein protein in the brain. DLB is the second most common cause of neurodegenerative dementia after Alzheimer's disease.
Ask a research question about Dementia with Lewy Bodies. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Dementia with Lewy Bodies
creation_date: '2025-12-24T16:57:05Z'
updated_date: '2026-04-22T20:13:21Z'
description: >
Dementia with Lewy Bodies (DLB) is a progressive neurodegenerative disorder
characterized by cognitive decline, visual hallucinations, parkinsonism, and
fluctuating cognition. It is pathologically defined by the presence of Lewy
bodies containing aggregated alpha-synuclein protein in the brain. DLB is the
second most common cause of neurodegenerative dementia after Alzheimer's disease.
category: Complex
disease_term:
preferred_term: Lewy body dementia
term:
id: MONDO:0007488
label: Lewy body dementia
parents:
- Dementia
- Neurodegenerative Disease
- Synucleinopathy
pathophysiology:
- name: Alpha-Synuclein Aggregation and Lewy Body Formation
description: >
DLB is characterized morphologically by widespread cortical and subcortical
alpha-synuclein aggregation forming Lewy bodies and Lewy neurites. The
alpha-synuclein pathology leads to neuronal dysfunction and is central to
the disease pathogenesis. The distribution and severity of Lewy body pathology
correlates with cognitive impairment and clinical features.
cell_types:
- preferred_term: neuron
term:
id: CL:0000540
label: neuron
downstream:
- target: Neuronal Death
- target: Cognitive Impairment and Dementia
evidence:
- reference: PMID:29222591
reference_title: "Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies."
supports: SUPPORT
snippet: "Both are characterized morphologically by widespread cortical and subcortical α-synuclein/Lewy body plus β-amyloid and tau pathologies."
explanation: This confirms that alpha-synuclein aggregation forming Lewy bodies is the central pathological feature of DLB, distributed throughout cortical and subcortical regions.
- name: Autophagy-Lysosome Dysfunction
description: >
Impaired autophagy and lysosomal functions are central to DLB pathogenesis.
Neurons are particularly vulnerable to autophagy-lysosomal defects due to their
postmitotic nature and polarized morphologies. Mutations in genes regulating
autophagy and lysosomal functions, particularly GBA, contribute to impaired
clearance of alpha-synuclein aggregates and damaged organelles. This dysfunction
creates a vicious cycle where accumulating protein aggregates further impair
the autophagic-lysosomal system.
cell_types:
- preferred_term: neuron
term:
id: CL:0000540
label: neuron
downstream:
- target: Alpha-Synuclein Aggregation and Lewy Body Formation
evidence:
- reference: PMID:39107446
reference_title: "Mechanisms of autophagy-lysosome dysfunction in neurodegenerative diseases."
supports: PARTIAL
snippet: "Autophagy is a lysosome-based degradative process used to recycle obsolete cellular constituents and eliminate damaged organelles and aggregate-prone proteins. Their postmitotic nature and extremely polarized morphologies make neurons particularly vulnerable to disruptions caused by autophagy-lysosomal defects, especially as the brain ages."
explanation: This establishes that autophagy-lysosome dysfunction is a fundamental mechanism in neurodegenerative diseases including Parkinson disease and related Lewy body disorders.
- reference: PMID:40598239
reference_title: "Current strategies in the management of dementia with lewy bodies and future directions based on disease pathophysiology."
supports: PARTIAL
snippet: "In particular, we highlight antibody-based therapies to attenuate protein aggregation, compounds that enhance the generation of cellular energy and autophagy-enhancing agents as particular areas of promise."
explanation: This confirms that autophagy dysfunction is a key therapeutic target in DLB, with autophagy-enhancing agents being developed as potential disease-modifying therapies.
- name: Neuronal Death
description: >
Progressive loss of neurons due to alpha-synuclein pathology and associated
proteinopathies, leading to brain atrophy particularly in cortical and limbic
regions. The neurodegeneration underlies the progressive cognitive decline and
other clinical features of DLB.
cell_types:
- preferred_term: neuron
term:
id: CL:0000540
label: neuron
evidence:
- reference: PMID:29222591
reference_title: "Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies."
supports: SUPPORT
snippet: "Intravitam PET and post-mortem studies revealed more pronounced cortical atrophy, elevated cortical and limbic Lewy pathologies."
explanation: This demonstrates that the alpha-synuclein pathology leads to cortical atrophy through neuronal loss, particularly pronounced in cortical and limbic regions.
phenotypes:
- category: Neurological
name: Visual Hallucinations
frequency: VERY_FREQUENT
diagnostic: true
notes: Recurrent complex visual hallucinations are a core clinical feature of DLB, occurring in 60-80% of patients. These hallucinations are typically well-formed images of people or animals and are a distinguishing feature from other dementias.
evidence:
- reference: PMID:29222591
reference_title: "Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies."
supports: SUPPORT
snippet: "The clinical features of DLB and PDD include cognitive impairment, parkinsonism, visual hallucinations, and fluctuating attention."
explanation: This confirms that visual hallucinations are a core clinical feature of dementia with Lewy bodies.
phenotype_term:
preferred_term: Visual hallucination
term:
id: HP:0002367
label: Visual hallucination
- category: Neurological
name: Parkinsonism
frequency: VERY_FREQUENT
diagnostic: true
notes: Parkinsonian motor features including rigidity, bradykinesia, and postural instability. Motor symptoms may present concurrently with or after cognitive symptoms, distinguishing DLB from Parkinson's disease dementia where motor symptoms precede dementia.
evidence:
- reference: PMID:29222591
reference_title: "Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies."
supports: SUPPORT
snippet: "Despite considerable clinical overlap, their diagnosis is based on an arbitrary distinction between the time of onset of motor and cognitive symptoms: dementia often preceding parkinsonism in DLB."
explanation: This confirms that parkinsonism is a core feature of DLB, with the temporal relationship to cognitive symptoms distinguishing it from Parkinson's disease dementia.
phenotype_term:
preferred_term: Parkinsonism
term:
id: HP:0001300
label: Parkinsonism
- category: Neurological
name: Dementia
frequency: VERY_FREQUENT
diagnostic: true
notes: Progressive cognitive impairment affecting attention, executive function, and visuospatial abilities. Cognitive fluctuations are characteristic, with marked variations in attention and alertness.
evidence:
- reference: PMID:29222591
reference_title: "Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies."
supports: SUPPORT
snippet: "The clinical features of DLB and PDD include cognitive impairment, parkinsonism, visual hallucinations, and fluctuating attention."
explanation: This confirms that cognitive impairment with characteristic fluctuating attention is a core feature of dementia with Lewy bodies.
phenotype_term:
preferred_term: Dementia
term:
id: HP:0000726
label: Dementia
- category: Neurological
name: REM Sleep Behavior Disorder
frequency: VERY_FREQUENT
diagnostic: true
notes: REM sleep behavior disorder (RBD) is a chronic sleep condition characterized by dream enactment and loss of REM atonia. Isolated RBD is a powerful early predictor of DLB, with cognitive decline beginning up to 10 years prior to phenoconversion. Attention and executive dysfunction in RBD patients strongly predict development of dementia.
evidence:
- reference: PMID:37461299
reference_title: "Prodromal dementia with Lewy bodies in REM sleep behavior disorder: A multicenter study."
supports: SUPPORT
snippet: "Isolated/idiopathic rapid eye movement sleep behavior disorder (iRBD) is a powerful early predictor of dementia with Lewy bodies (DLB) and Parkinson's disease (PD)."
explanation: This establishes that RBD is a prodromal marker for DLB, occurring years before dementia onset.
- reference: PMID:37461299
reference_title: "Prodromal dementia with Lewy bodies in REM sleep behavior disorder: A multicenter study."
supports: SUPPORT
snippet: "Cognitive decline in iRBD begins up to 10 years prior to phenoconversion. Attention and executive dysfunction are the strongest predictors of dementia in iRBD."
explanation: This demonstrates the temporal relationship between RBD and DLB, with attention/executive deficits predicting dementia phenoconversion.
phenotype_term:
preferred_term: REM sleep behavior disorder
term:
id: HP:5200291
label: REM sleep behavior disorder
genetic:
- name: APOE
association: APOE ε4 allele is a major genetic risk factor for DLB
notes: The APOE ε4 allele increases risk for DLB and is associated with more pronounced cortical Lewy pathology and higher prevalence of concomitant Alzheimer pathology. APOE represents a shared genetic risk factor between DLB and Alzheimer's disease.
evidence:
- reference: PMID:30097731
reference_title: "The Genetics of Dementia with Lewy Bodies: Current Understanding and Future Directions."
supports: SUPPORT
snippet: "DLB shares risk loci with AD, in the APOE E4 allele, and with PD, in variation at GBA and SNCA."
explanation: This confirms that the APOE ε4 allele is a shared genetic risk locus between DLB and Alzheimer's disease.
- reference: PMID:29222591
reference_title: "Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies."
supports: PARTIAL
snippet: "Intravitam PET and post-mortem studies revealed more pronounced cortical atrophy, elevated cortical and limbic Lewy pathologies (with APOE ε4)."
explanation: This demonstrates that APOE ε4 is associated with more pronounced Lewy pathology in DLB.
- name: GBA
association: GBA gene variants significantly increase risk for DLB
notes: Variants in the glucocerebrosidase (GBA) gene are important genetic risk factors for DLB. GBA mutation carriers have earlier age of onset, more severe cognitive impairment, and more rapid symptom progression. Specific variants including N370S, E326K, and L444P are strongly associated with DLB.
evidence:
- reference: PMID:35332438
reference_title: "Effect of GBA gene variants on clinical characteristics of dementia with Lewy bodies: a review and meta-analyses."
supports: SUPPORT
snippet: "GBA variants increased the risk of DLB, especially N370S, E326K, and L444P which are strongly associated with DLB, but T369M was not. Patients harbouring GBA variants have an earlier age of onset, more severe cognitive impairment, and rapid symptom progression."
explanation: This meta-analysis confirms that specific GBA variants are strongly associated with DLB and correlate with earlier onset and more severe clinical presentation.
- reference: PMID:28734699
reference_title: "An update on the genetics of dementia with Lewy bodies."
supports: SUPPORT
snippet: "More recently, association and exome sequencing studies in larger groups have been conducted, and have shown that several variants in GBA and the APOE ε4 allele are important genetic risk factors for DLB."
explanation: This review confirms that GBA variants are important genetic risk factors for dementia with Lewy bodies.
- reference: PMID:30097731
reference_title: "The Genetics of Dementia with Lewy Bodies: Current Understanding and Future Directions."
supports: SUPPORT
snippet: "DLB shares risk loci with AD, in the APOE E4 allele, and with PD, in variation at GBA and SNCA."
explanation: This confirms that GBA represents a shared genetic risk locus between DLB and Parkinson's disease.
- name: SNCA
association: SNCA gene variants associated with DLB risk
notes: The SNCA gene encoding alpha-synuclein shows genetic association with DLB, representing a shared genetic risk factor with Parkinson's disease. Variation at SNCA influences risk for developing Lewy body pathology.
evidence:
- reference: PMID:30097731
reference_title: "The Genetics of Dementia with Lewy Bodies: Current Understanding and Future Directions."
supports: SUPPORT
snippet: "DLB shares risk loci with AD, in the APOE E4 allele, and with PD, in variation at GBA and SNCA."
explanation: This confirms that SNCA represents a shared genetic risk locus between DLB and Parkinson's disease.
treatments:
- name: Cholinesterase Inhibitors
description: Cholinesterase inhibitors such as rivastigmine, donepezil, and galantamine are used to manage cognitive symptoms in DLB. These medications address the cholinergic deficits present in the disease and can provide mild symptomatic benefit for cognitive and behavioral symptoms.
evidence:
- reference: PMID:29222591
reference_title: "Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies."
supports: SUPPORT
snippet: "Clinical management of both disorders includes cholinesterase inhibitors, other pharmacologic and nonpharmacologic strategies, but these have only a mild symptomatic effect."
explanation: This confirms that cholinesterase inhibitors are part of standard clinical management for DLB, though they provide only mild symptomatic benefit.
treatment_term:
preferred_term: cholinesterase inhibitor therapy
term:
id: MAXO:0000645
label: acetylcholinesterase inhibitor therapy
- name: Symptomatic Management
description: No disease-modifying treatments currently available. Management focuses on symptomatic treatment of cognitive, motor, and psychiatric symptoms. Includes both pharmacological approaches (cautious use of antipsychotics due to sensitivity, dopaminergic therapy for parkinsonism) and non-pharmacological strategies including behavioral interventions and caregiver support.
evidence:
- reference: PMID:29222591
reference_title: "Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies."
supports: SUPPORT
snippet: "Currently, no disease-modifying therapies are available."
explanation: This confirms that no disease-modifying therapies are currently available for DLB, with treatment limited to symptomatic management.
treatment_term:
preferred_term: supportive care
term:
id: MAXO:0000950
label: supportive care
classifications:
harrisons_chapter:
- classification_value: nervous system disorder
- classification_value: neurodegenerative disease
mechanistic_category:
- classification_value: synucleinopathy
Pathophysiology description (narrative) DLB is a synucleinopathy defined by intraneuronal α‑synuclein aggregates (Lewy bodies/neurites) with widespread network dysfunction affecting attention, executive and visuospatial domains, fluctuating cognition, visual hallucinations, parkinsonism, REM sleep behavior disorder (RBD), and autonomic failure. Contemporary evidence suggests that Lewy body burden correlates imperfectly with neuronal loss and clinical severity; smaller oligomeric/nonfibrillar α‑syn species and their interactions with organelles (mitochondria, lysosomes) and synapses likely drive toxicity (Erskine & Taylor 2025) (erskine2025currentstrategiesin pages 5-6, erskine2025currentstrategiesin pages 4-5). Genetics and biomarker data reinforce a multi‑system disease in which autophagy–lysosome (GBA, TMEM175, SCARB2, CTSB), mitochondrial (complex I) impairment, and co‑pathology from Alzheimer’s disease (AD; Aβ/tau) critically modify phenotype and progression (Erskine & Taylor 2025; Jellinger 2025; Barba 2024) (erskine2025currentstrategiesin pages 5-6, jellinger2025comorbidpathologiesand pages 7-8, jellinger2025comorbidpathologiesand pages 13-14). A growing view considers Parkinson’s disease dementia (PDD) and DLB as manifestations along a single Lewy body disease continuum, with advanced “Lewy body dementia” representing extensive neocorticolimbic Lewy pathology plus frequent AD co-pathology (Borghammer et al., 2024) (borghammer2024parkinson’sdiseaseand pages 1-2).
Recent developments and latest research - Seed amplification assays (SAA, RT‑QuIC) and staging sensitivity: CSF RT‑QuIC shows high specificity and sensitivity for limbic/neocortical stages, but lower sensitivity at early/focal stages; quantitative kinetics (lag phase; number of positive replicates) correlate with LB pathology burden (Bentivenga et al., 2024; Peña‑Bautista et al., 2023) (, , ; , , ). SAA is emerging as a pathology-specific biomarker to support biological definitions of Lewy body disease (Wyman‑Chick et al., 2024; Erskine & Taylor 2025) (wymanchick2024differentiatingprodromaldementia pages 1-2, erskine2025currentstrategiesin pages 1-2). - Neurotransmitter network dysfunction: Dopaminergic loss measurable by DAT SPECT is a cornerstone biomarker; systematic reviews confirm diagnostic utility for DLB and support integration into criteria (Jreige et al., 2023) (erskine2025currentstrategiesin pages 1-2). Cholinergic degeneration of the nucleus basalis of Meynert and projections is robustly linked to attention/visuospatial deficits in PD/LBD and can be measured with molecular imaging and MRI tractography (Schumacher et al., 2023/2022; reviewed within Wyman‑Chick 2024) (wymanchick2024differentiatingprodromaldementia pages 1-2). - AD co‑pathology and prognosis: Approximately half of LBD cases harbor AD pathology; AD biomarker positivity associates with accelerated decline and poorer survival, and shifts the clinical presentation toward early dementia (Barba et al., 2024; Jellinger 2025) (jellinger2025comorbidpathologiesand pages 13-14, jellinger2025comorbidpathologiesand pages 7-8). This underpins growing use of blood/CSF Aβ and p‑tau assays to stratify DLB.
Core pathophysiology - Primary mechanisms: α‑syn misfolding/aggregation with putative oligomer toxicity; impaired autophagy–lysosome flux and mitophagy; mitochondrial complex I deficits/oxidative stress; synaptic dysfunction; neurotransmitter network failure (dopamine/cholinergic); variable neuroinflammation; and frequent AD co‑pathology that synergizes with Lewy pathology (Erskine & Taylor 2025; Borghammer 2024; Barba 2024; Jellinger 2025) (erskine2025currentstrategiesin pages 5-6, borghammer2024parkinson’sdiseaseand pages 1-2, jellinger2025comorbidpathologiesand pages 13-14, jellinger2025comorbidpathologiesand pages 7-8). - Dysregulated molecular pathways: autophagy (GO:0006914), lysosomal proteolysis (GO:0006508), endolysosomal trafficking (GO:0006897), mitochondrial oxidative phosphorylation (GO:0006119; complex I), synaptic transmission (GO:0007268), cholinergic (GO:0007271) and dopaminergic (GO:0001963) signaling, innate immune activation (GO:0006954) (erskine2025currentstrategiesin pages 5-6, jellinger2025comorbidpathologiesand pages 13-14, erskine2025currentstrategiesin pages 1-2). - Affected cellular processes: impaired clearance of α‑syn and damaged organelles, sequestration of organelles in LBs, synaptic failure, bioenergetic stress, axonal transport defects, and region‑selective neuron vulnerability (nucleus basalis of Meynert, nigrostriatal neurons) (Erskine & Taylor 2025; Jreige 2023; Schumacher 2023) (erskine2025currentstrategiesin pages 5-6, erskine2025currentstrategiesin pages 1-2).
Key molecular players - Genes/Proteins: SNCA (α‑syn; aggregation core), GBA (glucocerebrosidase deficiency → lysosomal dysfunction), LRRK2 (vesicular/lysosomal modulation), APOE (AD co‑pathology risk and progression), MAPT (tau co‑pathology), TMEM175 (lysosomal channel), BIN1 (endocytosis), CTSB (lysosomal protease), SCARB2 (LIMP‑2 trafficking of GCase) (Erskine & Taylor 2025; Jellinger 2025) (erskine2025currentstrategiesin pages 5-6, jellinger2025comorbidpathologiesand pages 13-14, jellinger2025comorbidpathologiesand pages 7-8). - Chemical entities: acetylcholine (CHEBI:15346) and dopamine (CHEBI:18243) reflect neurotransmitter vulnerabilities; biomarker entities include p‑tau and Aβ species (Barba 2024; Jreige 2023) (erskine2025currentstrategiesin pages 1-2). - Cell types: basal forebrain cholinergic neurons (CL:0000108), nigrostriatal dopaminergic neurons (CL:0002315), cortical pyramidal neurons, striatal interneurons, microglia (CL:0000129), astrocytes (CL:0000127), oligodendrocytes (Wyman‑Chick 2024; Schumacher 2023; Borghammer 2024) (wymanchick2024differentiatingprodromaldementia pages 1-2, borghammer2024parkinson’sdiseaseand pages 1-2). - Anatomical locations: neocortex (UBERON:0001950), limbic cortex/amygdala (UBERON:0001871), brainstem RBD circuitry, substantia nigra (UBERON:0002038), nucleus basalis of Meynert (UBERON:0001881), striatum (Borghammer 2024; Wyman‑Chick 2024; Jreige 2023) (borghammer2024parkinson’sdiseaseand pages 1-2, wymanchick2024differentiatingprodromaldementia pages 1-2, erskine2025currentstrategiesin pages 1-2).
Biological processes for GO annotation - Protein aggregation and clearance: autophagy (GO:0006914), macroautophagy, mitophagy; lysosomal proteolysis (GO:0006508) (Erskine & Taylor 2025) (erskine2025currentstrategiesin pages 5-6). - Mitochondrial function: oxidative phosphorylation (GO:0006119); respiratory complex I (GO:0005747 component) (Erskine & Taylor 2025) (erskine2025currentstrategiesin pages 5-6). - Synaptic and neurotransmitter signaling: synaptic transmission (GO:0007268), cholinergic (GO:0007271), dopaminergic (GO:0001963) (Wyman‑Chick 2024; Jreige 2023) (wymanchick2024differentiatingprodromaldementia pages 1-2, erskine2025currentstrategiesin pages 1-2). - Innate immune responses: inflammatory response (GO:0006954) with glial markers GFAP, sTREM2 and NfL (Jellinger 2025) (jellinger2025comorbidpathologiesand pages 13-14).
Cellular components - Sites of pathology: synapse (GO:0045202) where α‑syn oligomers impair transmission; lysosome (GO:0005764) for autophagic flux; mitochondrion (GO:0005739), respiratory chain complex I (GO:0005747); extracellular region (GO:0005576) for biofluid biomarkers (Bentivenga 2024; Erskine & Taylor 2025) (erskine2025currentstrategiesin pages 5-6).
Disease progression (sequence of events) - Prodromal stage with isolated RBD (iRBD): pathophysiology likely begins in lower brainstem REM atonia circuits, then spreads rostrally (Borghammer 2024; Wyman‑Chick 2024) (borghammer2024parkinson’sdiseaseand pages 1-2, wymanchick2024differentiatingprodromaldementia pages 1-2). - Limbic/neocortical spread: cognitive fluctuations, visuospatial/executive deficits, complex visual hallucinations, and early attentional impairment emerge as pathology accrues; cholinergic basal forebrain degeneration contributes to cortical network dysfunction (Schumacher 2023; Borghammer 2024) (borghammer2024parkinson’sdiseaseand pages 1-2). - Modification by co‑pathology: elevated AD biomarkers (Aβ, p‑tau) predict faster decline, higher risk of dementia-first phenotypes and mortality in LBD (Barba 2024; Jellinger 2025) (jellinger2025comorbidpathologiesand pages 13-14).
Phenotypic manifestations and mechanistic links - Clinical phenotypes: core features include fluctuating cognition (HP:0031812), well‑formed visual hallucinations (HP:0002367), parkinsonism (HP:0000007), RBD (HP:0002365), severe neuroleptic sensitivity (HP:0002664), and autonomic dysfunction (HP:0002576). DAT SPECT abnormalities reflect nigrostriatal loss; cholinergic imaging/tractography relate to attention/visuospatial deficits; AD biomarker positivity relates to amnestic shifts and faster progression (Wyman‑Chick 2024; Jreige 2023; Barba 2024) (wymanchick2024differentiatingprodromaldementia pages 1-2, erskine2025currentstrategiesin pages 1-2).
Recent biomarker developments and accuracy - α‑Syn SAA (CSF): pooled sensitivity/specificity ~0.94/0.96 vs controls and ~0.95/0.88 vs AD; sensitivity is lower in early/focal LBD, highest in limbic/neocortical stages; kinetic parameters (lag phase, positive replicates) scale with pathology burden (Peña‑Bautista 2023; Bentivenga 2024) (, ). - DAT SPECT: strong diagnostic performance and widely used in criteria; longitudinal data in MCI-LB show ~−5.6% annual decline in striatal binding, with ~6 years for a normal scan to become abnormal at group level (Jreige 2023; Durcan 2023) (erskine2025currentstrategiesin pages 1-2). - Cardiac MIBG SPECT: recognized indicative biomarker for sympathetic denervation in DLB; often complementary to DAT imaging in criteria (Wyman‑Chick 2024) (wymanchick2024differentiatingprodromaldementia pages 1-2). - Fluid/glial markers: NfL, GFAP, sTREM2 elevated in DLB and higher with AD co‑pathology; may aid prognostication and stratification (Jellinger 2025) (jellinger2025comorbidpathologiesand pages 13-14).
Expert opinions and synthesis - Unified Lewy body disease framework: PDD and DLB are indistinguishable at advanced stages; phenotypic differences are driven by timing, individual risk and co‑pathologies; biological definitions and multi‑modal biomarkers should supersede legacy splits (Borghammer 2024) (borghammer2024parkinson’sdiseaseand pages 1-2). - Therapeutic implications: symptom‑targeted care remains standard (cholinesterase inhibitors for cognition; careful dopaminergic therapy), while disease‑modifying strategies are likely to require multi‑target approaches addressing α‑syn aggregation, mitochondrial bioenergetics, and autophagy‑lysosome function (Erskine & Taylor 2025) (erskine2025currentstrategiesin pages 1-2, erskine2025currentstrategiesin pages 5-6).
Annotations and ontology mapping - Genes/proteins: HGNC SNCA, GBA, LRRK2, APOE, MAPT, TMEM175, BIN1, CTSB, SCARB2. - Biological processes: GO:0006914, GO:0006508, GO:0006897, GO:0006119, GO:0007268, GO:0007271, GO:0001963, GO:0006954. - Cellular components: GO:0045202, GO:0005764, GO:0005739, GO:0005747, GO:0005576. - Cell types (CL): CL:0000108, CL:0002315, CL:0000129, CL:0000127. - Anatomy (UBERON): UBERON:0001950, UBERON:0001871, UBERON:0002038, UBERON:0001881. - Chemicals (CHEBI): CHEBI:15346, CHEBI:18243.
Entity summary artifact | Entity (type) | Role in DLB pathophysiology (concise; citations) | Pathways / Processes (GO term — name and ID) | Cellular components (GO CC — name and ID) | Primary cell types (CL — name and ID) | Key anatomical sites (UBERON — name and ID) | Cross-refs (HGNC / CHEBI) | |---|---|---|---|---|---|---| | SNCA (gene / protein) | α‑Syn aggregation → Lewy body/neurite formation; oligomeric species likely neurotoxic (erskine2025currentstrategiesin pages 5-6, borghammer2024parkinson’sdiseaseand pages 1-2) | GO:0007268 — synaptic transmission; GO:0030434 — ubiquitin-dependent protein catabolic process | GO:0045202 — synapse; GO:0005739 — mitochondrion | Cholinergic basal forebrain neurons; cortical excitatory neurons | Neocortex; substantia nigra; brainstem | HGNC: SNCA | | GBA (gene) | Reduced glucocerebrosidase → lysosomal dysfunction, impaired α‑syn clearance; genetic risk modifier (jellinger2025comorbidpathologiesand pages 13-14, erskine2025currentstrategiesin pages 5-6) | GO:0006914 — autophagy; GO:0006629 — lipid metabolic process | GO:0005764 — lysosome | Neurons (broad vulnerability) | Substantia nigra; limbic regions | HGNC: GBA | | LRRK2 (gene) | Kinase alters vesicular trafficking/lysosomal pathways; implicated in synucleinopathy overlap (jellinger2025comorbidpathologiesand pages 13-14) | GO:0007049 — vesicle-mediated transport; GO:0006914 — autophagy (modulation) | GO:0005773 — vacuole / endolysosomal compartment | Neurons; peripheral/central immune cells (microglia) | Substantia nigra; cortex | HGNC: LRRK2 | | APOE (gene) | Modifies AD co-pathology risk and progression in DLB; influences Aβ/tau interactions (jellinger2025comorbidpathologiesand pages 13-14, jellinger2025comorbidpathologiesand pages 7-8) | GO:0006954 — inflammatory response; GO:0007165 — signal transduction | GO:0005576 — extracellular region | Astrocytes (primary APOE source); neurons affected | Hippocampus; cortex | HGNC: APOE | | MAPT (gene) | Tau co-pathology common in DLB and accelerates cognitive decline (jellinger2025comorbidpathologiesand pages 13-14) | GO:0030424 — axon; GO:0019901 — protein stabilization | GO:0008021 — tau-protein binding | Cortical pyramidal neurons | Hippocampus; temporal cortex | HGNC: MAPT | | TMEM175 (gene) | Lysosomal ion channel affecting lysosome function; GWAS locus shared with synucleinopathies (erskine2025currentstrategiesin pages 5-6, jellinger2025comorbidpathologiesand pages 13-14) | GO:0005764 — lysosome organization / function | GO:0005764 — lysosome | Neurons (lysosomal homeostasis) | Cortex; substantia nigra | HGNC: TMEM175 | | BIN1 (gene) | Endocytic/membrane trafficking role; genetic overlap with AD/DLB (jellinger2025comorbidpathologiesand pages 13-14) | GO:0006897 — endocytosis; GO:0046558 — membrane lipid distribution | GO:0005783 — endoplasmic reticulum membrane | Neurons; glia | Neocortex; hippocampus | HGNC: BIN1 | | CTSB (gene) | Cathepsin B — lysosomal protease altered in proteomics; linked to autophagy/lysosomal dysfunction (jellinger2025comorbidpathologiesand pages 8-10, jellinger2025comorbidpathologiesand pages 13-14) | GO:0006508 — proteolysis; GO:0005764 — lysosome | GO:0005764 — lysosome | Neurons; lysosome-rich cells | Cortex; limbic regions | HGNC: CTSB | | SCARB2 (gene) | LIMP‑2 mediates GCase trafficking to lysosome; GWAS locus in synucleinopathies (jellinger2025comorbidpathologiesand pages 13-14) | GO:0005783 — ER membrane; GO:0005764 — lysosome | GO:0005764 — lysosome; endosomal membrane | Neurons | Substantia nigra; cortex | HGNC: SCARB2 | | Cholinergic transmission (ACh) | Early cholinergic failure drives cognitive/attentional deficits; therapeutic target for symptoms (erskine2025currentstrategiesin pages 1-2, wymanchick2024differentiatingprodromaldementia pages 1-2) | GO:0007271 — synaptic transmission, cholinergic | GO:0045202 — synapse | Cholinergic basal forebrain neurons (NBM) | Nucleus basalis of Meynert; cortex | CHEBI:15346 (acetylcholine) | | Dopaminergic transmission (dopamine) | Nigrostriatal dopaminergic loss → parkinsonism; DAT imaging diagnostic utility (borghammer2024parkinson’sdiseaseand pages 1-2) | GO:0001963 — synaptic transmission, dopaminergic | GO:0043035 — neuron projection | Nigrostriatal dopaminergic neurons | Substantia nigra pars compacta; striatum | CHEBI:18243 (dopamine) | | Autophagy–lysosome pathway (process) | Impaired clearance of α‑syn and damaged organelles central to DLB pathogenesis (erskine2025currentstrategiesin pages 5-6) | GO:0006914 — autophagy | GO:0005764 — lysosome | Neurons; microglia (autophagy engagement) | Cortex; brainstem | — | | Mitochondrial OXPHOS / Complex I (process) | Mitochondrial dysfunction / complex I deficits linked to neuronal vulnerability and α‑syn toxicity (erskine2025currentstrategiesin pages 5-6) | GO:0006119 — oxidative phosphorylation | GO:0005739 — mitochondrion; GO:0005747 — respiratory chain complex I | Vulnerable neurons (SNpc dopaminergic; basal forebrain) | Substantia nigra; basal forebrain | — | | Microglial activation / neuroinflammation (process) | Variable central/peripheral innate immune activation; sTREM2, GFAP, cytokine signals reported (jellinger2025comorbidpathologiesand pages 13-14, erskine2025currentstrategiesin pages 1-2) | GO:0006954 — inflammatory response; GO:0002376 — immune system process | GO:0005576 — extracellular region (secreted mediators) | Microglia (activated); astrocytes | Cortex; limbic regions | HGNC: TREM2 | | α‑Synuclein oligomers (protein species) | Oligomeric α‑syn species considered highly toxic at synapses/mitochondria; PTMs (pS129) prevalent but role complex (erskine2025currentstrategiesin pages 5-6, erskine2025currentstrategiesin pages 4-5) | GO:0030970 — protein-containing complex assembly; GO:0030424 — axon | GO:0045202 — synapse; GO:0005739 — mitochondrion | Presynaptic terminals of vulnerable neurons | Neocortex; limbic cortex; brainstem | — | | Seed amplification assay (biomarker concept) | RT‑QuIC/PMCA detect misfolded α‑syn seeds in CSF/skin; high sensitivity for limbic/neocortical stages, lower in focal/early disease (, ) | (assay concept; not a GO biological process) | GO:0005576 — extracellular region (biofluids sampled: CSF, plasma) | N/A (assay-based readout) | Cerebrospinal fluid; skin biopsy | — |
Table: Table mapping key genes/proteins, processes, cell types and anatomical sites relevant to Dementia with Lewy Bodies, with representative GO/GO-CC/CL/UBERON terms and literature context IDs for evidence-based annotation.
Evidence items with URLs and dates (selected) - Borghammer P, Okkels N, Weintraub D. Parkinson’s Disease and Dementia with Lewy Bodies: One and the Same. Journal of Parkinson’s Disease. 2024 Apr;14:383–397. https://doi.org/10.3233/jpd-240002 (borghammer2024parkinson’sdiseaseand pages 1-2) - Wyman‑Chick KA, et al. Differentiating Prodromal DLB from Prodromal AD. Neurology and Therapy. 2024 May;13:885–906. https://doi.org/10.1007/s40120-024-00620-x (wymanchick2024differentiatingprodromaldementia pages 1-2) - Jreige M, et al. Diagnostic performance of DAT SPECT in DLB (systematic review). Eur J Nucl Med Mol Imaging. 2023 Mar;50:1988–2035. https://doi.org/10.1007/s00259-023-06154-y (erskine2025currentstrategiesin pages 1-2) - Durcan R, et al. Serial Nigrostriatal Imaging in MCI-LB. Neurology. 2023 Sep;101. https://doi.org/10.1212/WNL.0000000000207621 () - Bentivenga GM, et al. SAA performance vs stage/burden. Acta Neuropathol. 2024 Jan;147. https://doi.org/10.1007/s00401-023-02663-0 () - Peña‑Bautista C, et al. RT‑QuIC meta-analysis in DLB. Front Mol Biosci. 2023 May;10. https://doi.org/10.3389/fmolb.2023.1193458 () - Barba L, et al. Clinical and diagnostic implications of AD co‑pathology in LBD. Brain. 2024 Jul;147:3325–3343. https://doi.org/10.1093/brain/awae203 () - Erskine D, Taylor J‑P. Management strategies and pathophysiology. Mol Neurodegener. 2025 Jul. https://doi.org/10.1186/s13024-025-00856-7 (erskine2025currentstrategiesin pages 5-6, erskine2025currentstrategiesin pages 4-5, erskine2025currentstrategiesin pages 1-2) - Jellinger KA. Comorbid pathologies and impact in DLB. Int J Mol Sci. 2025 Aug;26:7674. https://doi.org/10.3390/ijms26167674 (jellinger2025comorbidpathologiesand pages 8-10, jellinger2025comorbidpathologiesand pages 13-14, jellinger2025comorbidpathologiesand pages 7-8)
Limitations and open questions - While α‑syn SAA is highly accurate overall, sensitivity drops in early/focal Lewy pathology. Standardization and quantitative SAA formats (e.g., lag phase, replicate counts) are active development areas. Co‑pathology modifies phenotypes and may require composite biomarker panels for precision stratification (Bentivenga 2024; Peña‑Bautista 2023) ().
References are cited inline by context IDs. Where used, 2023–2024 publications were prioritized; a small number of 2025 reviews were included for mechanistic synthesis and are flagged in citations above.
References
(erskine2025currentstrategiesin pages 5-6): Daniel Erskine and John-Paul Taylor. Current strategies in the management of dementia with lewy bodies and future directions based on disease pathophysiology. Molecular Neurodegeneration, Jul 2025. URL: https://doi.org/10.1186/s13024-025-00856-7, doi:10.1186/s13024-025-00856-7. This article has 0 citations and is from a highest quality peer-reviewed journal.
(erskine2025currentstrategiesin pages 4-5): Daniel Erskine and John-Paul Taylor. Current strategies in the management of dementia with lewy bodies and future directions based on disease pathophysiology. Molecular Neurodegeneration, Jul 2025. URL: https://doi.org/10.1186/s13024-025-00856-7, doi:10.1186/s13024-025-00856-7. This article has 0 citations and is from a highest quality peer-reviewed journal.
(jellinger2025comorbidpathologiesand pages 7-8): Kurt A. Jellinger. Comorbid pathologies and their impact on dementia with lewy bodies—current view. International Journal of Molecular Sciences, 26:7674, Aug 2025. URL: https://doi.org/10.3390/ijms26167674, doi:10.3390/ijms26167674. This article has 2 citations and is from a poor quality or predatory journal.
(jellinger2025comorbidpathologiesand pages 13-14): Kurt A. Jellinger. Comorbid pathologies and their impact on dementia with lewy bodies—current view. International Journal of Molecular Sciences, 26:7674, Aug 2025. URL: https://doi.org/10.3390/ijms26167674, doi:10.3390/ijms26167674. This article has 2 citations and is from a poor quality or predatory journal.
(borghammer2024parkinson’sdiseaseand pages 1-2): Per Borghammer, Niels Okkels, and Daniel Weintraub. Parkinson’s disease and dementia with lewy bodies: one and the same. Journal of Parkinson's Disease, 14:383-397, Apr 2024. URL: https://doi.org/10.3233/jpd-240002, doi:10.3233/jpd-240002. This article has 45 citations.
(wymanchick2024differentiatingprodromaldementia pages 1-2): Kathryn A. Wyman-Chick, Parichita Chaudhury, Ece Bayram, Carla Abdelnour, Elie Matar, Shannon Y. Chiu, Daniel Ferreira, Calum A. Hamilton, Paul C. Donaghy, Federico Rodriguez-Porcel, Jon B. Toledo, Annegret Habich, Matthew J. Barrett, Bhavana Patel, Alberto Jaramillo-Jimenez, Gregory D. Scott, and Joseph P. M. Kane. Differentiating prodromal dementia with lewy bodies from prodromal alzheimer’s disease: a pragmatic review for clinicians. Neurology and Therapy, 13:885-906, May 2024. URL: https://doi.org/10.1007/s40120-024-00620-x, doi:10.1007/s40120-024-00620-x. This article has 19 citations and is from a domain leading peer-reviewed journal.
(erskine2025currentstrategiesin pages 1-2): Daniel Erskine and John-Paul Taylor. Current strategies in the management of dementia with lewy bodies and future directions based on disease pathophysiology. Molecular Neurodegeneration, Jul 2025. URL: https://doi.org/10.1186/s13024-025-00856-7, doi:10.1186/s13024-025-00856-7. This article has 0 citations and is from a highest quality peer-reviewed journal.
(jellinger2025comorbidpathologiesand pages 8-10): Kurt A. Jellinger. Comorbid pathologies and their impact on dementia with lewy bodies—current view. International Journal of Molecular Sciences, 26:7674, Aug 2025. URL: https://doi.org/10.3390/ijms26167674, doi:10.3390/ijms26167674. This article has 2 citations and is from a poor quality or predatory journal.